Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years

Autor: Peter Hohenberger, Jean-Yves Blay, M. Ouali, Nicolas Penel, M. van Glabbeke, Sandrine Marreaud

Publikováno v: Annals of Oncology. 22:1266-1272

Background The prognosis of advanced soft tissue sarcoma remains poor. Many phase II trials investigating new regimens have been published in the last 10 years. Materials and methods Full English-language reports of phase II clinical trials from Janu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7029738e1a29767cea0677640931bb28
https://doi.org/10.1093/annonc/mdq608

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Autor: Shreyaskumar Patel, Carine Bellera, Hans Gelderblom, M. Delannes, Robert J. Grimer, Chandrajit P. Raut, Sophie Piperno-Neumann, Odile Oberlin, Chiara Mussi, Rolf D. Issels, Binh Bui, J.-Y. Blay, M. van Glabbeke, M. Ouali, Antoine Italiano, Alessandro Gronchi, O.S. Nielsen, E. Stoeckle, Peter Hohenberger, Simone Mathoulin-Pélissier, Stefan Sleijfer, Nicolas Penel, Rick L. Haas, Suzanne George, C. Le Pechoux, I.L. Ray-Coquard, M. Fiore, S. Bonvalot, Florence Duffaud, Robert S. Benjamin, F. Bonnetain, V. Jooste, Pascale Grosclaude, Thomas Filleron, Scott M. Schuetze, Piotr Rutkowski, F. Collin, Anders Krarup-Hansen, Penella J. Woll, Sophie Gourgou-Bourgade, Thomas F. DeLaney, Paolo G. Casali, Tienhan Sandrine Dabakuyo, Saskia Litière

Publikováno v: Annals of Oncology
Annals of Oncology, Elsevier, 2015, ⟨10.1093/annonc/mdu360⟩
Annals of Oncology, 26(5), 865-872. Elsevier Ltd.
Annals of Oncology, 26(5), 865-872
Bellera, C A, Penel, N, Ouali, M, Bonvalot, S, Casalli, P G, Nielsen, O S, Delannes, M, Litière, S, Bonnetain, F, Dabakuyo, T S, Benjamin, R, Blay, J Y, Bui, B N, Collin, F, Delaney, T F, Duffaud, F, Filleron, T, Fiore, M, Gelderblom, H, George, S, Grimer, R, Grosclaude, P, Gronchi, A, Haas, R, Hohenberger, P, Issels, R, Italiano, A, Jooste, V, Krarup-Hansen, A, Le Péchoux, C, Mussi, C, Oberlin, O, Patel, S, Piperno-Neumann, S, Raut, C, Ray-Coquard, I, Rutkowski, P, Schuetze, S, Sleijder, S, Stoeckle, E, Van Glabbeke, M, Woll, P, Gourgou-Bourgade, S & Mathoulin-Pélissier, S 2015, ' Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) ', Annals of Oncology, vol. 26, no. 5, pp. 865-872 . https://doi.org/10.1093/annonc/mdu360

The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of time-to-event end points in cancer randomized controlled trials. We relied on a consensus method bas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::663ffb772cb995a75920d599a504734e
https://doi.org/10.1093/annonc/mdu360

Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas

Autor: Sandrine Marreaud, Peter Reichardt, Daniel Pink, Søren Daugaard, T B Christensen, J.-Y. Blay, Ole S. Nielsen, M. van Glabbeke, Cédric Hermans, Ian Judson

Publikováno v: Nielsen, O S, Reichardt, P, Christensen, T B, Pink, D, Daugaard, S, Hermans, C, Marreaud, S, van Glabbeke, M, Blay, J & Judson, I 2006, ' Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas ', European Journal of Cancer, vol. 42, no. 14, pp. 2303-9 . https://doi.org/10.1016/j.ejca.2006.04.011

This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx®) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas. Five dose levels (L) were studied: Caelyx® 30 mg/m2 (L1–4)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0104d95fa57c977eda77fe238f6d6c1
https://doi.org/10.1016/j.ejca.2006.04.011

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Autor: Michel Stul, H. Vranck, Maria Debiec-Rychter, Anne Hagemeijer, Ian Judson, Bartosz Wasag, Raphael Sciot, M. Brown, A.T. Van Oosterom, H. Dumez, Michelle Scurr, M. van Glabbeke, Jaap Verweij, Sasa Dimitrijevic

Publikováno v: European Journal of Cancer, 40, 689-695. Elsevier Ltd.

Previous studies have shown that activating mutations of c-KIT/PDGFRA, potential therapeutic targets for imatinib mesylate, are implicated in the pathophysiology of gastrointestinal stromal tumours (GISTs). In this study, GISTs from 37 patients enrol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7c6e6a35cdd4ae5cab942faae6e784b
https://doi.org/10.1016/j.ejca.2003.11.025

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

Autor: L. Svancarova, Jaap Verweij, Ian Judson, P Dombernowsky, Cédric Hermans, A. van Oosterom, D. Spooner, Krzysztof Krzemieniecki, Henning T. Mouridsen, M. van Glabbeke, Ole S. Nielsen

Publikováno v: van Oosterom, A T, Mouridsen, H T, Nielsen, O S, Dombernowsky, P, Krzemieniecki, K, Judson, I, Svancarova, L, Spooner, D, Hermans, C, Van Glabbeke, M & Verweij, J 2002, ' Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced soft tissue sarcoma patients ', European Journal of Cancer, vol. 38, no. 18, pp. 2397-406 . https://doi.org/10.1016/S0959-8049(02)00491-4
European Journal of Cancer, 38, 2397-2406. Elsevier Ltd.

The aim of this phase 11 study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy. Two different schedules of ifosfamide were investigated in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cfae226d4b530bff02663fe87615d3b
https://doi.org/10.1016/s0959-8049(02)00491-4